An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00737009

NIS-OVN-ARI-2008/1

Details and patient eligibility

About

The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.

Enrollment: 259 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
• Histologically or cytologically proven to be HR+(ER or PR +)
• No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
• Provision of written informed consent

Exclusion criteria

• Recurrence of breast cancer
• Known hypersensitivity to anastrozole or to any of its excipients
• Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
• Women who does not agreed to participate the program